Anrukinzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anrukinzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target IL13
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6452H9954N1714O2024S46
Molar mass 145.4 kg/mol
 NYesY (what is this?)  (verify)

Anrukinzumab (IMA-638[1]) is a humanized monoclonal antibody designed for the treatment of asthma.[2]

Anrukinzumab was developed by Wyeth.

References[edit]

  1. ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008. 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.